MOLLY BROWN: Open Payments
NPI 1750158473 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$652 in 44 payments from 12 companies in 2025. Trend: 2023 $28 · 2024 $679 · 2025 $652
Food & beverage: $652
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $302 |
| Novo Nordisk Inc | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Lilly USA, LLC | 3 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| PFIZER INC. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
| Janssen Pharmaceuticals, Inc | 1 | $21 |
| MAYNE PHARMA COMMERCIAL LLC | 2 | $20 |
Products named: UBRELVY, QULIPTA, VRAYLAR, TRINTELLIX, Wegovy, JARDIANCE, CAPLYTA, REXULTI.
Industry payments across NE — which companies pay providers there.
